glp 1 agonist clinical trials trial GLP-1R Agonists for Weight Loss Continued growth for GLP-1 receptor

De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT

An elevated resting heart rate can increase long-term cardiovascular risk, and regulators need robust data confirming that the metabolic benefits outweigh this potential downside

Clinicians may consider closer INR monitoring due to potential increased INR variability after GLP-1 RA initiation

This duality underscores the therapeutic potential of targeting microbiotaGLP-1 interactions in metabolic disorders

Results As described in Figures 1 and 2, a total of 2,232 articles were found in an initial Medline search, of which 846 articles were regarding GLP-1RA and 1,386 articles were related to SGLT2-I

Although GLP-1RAs improve mobility and reduce body weight, some patients decrease physical activity during treatment due to fatigue or altered energy perception